相关实验视频

Updated: Jun 29, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

在三阴性乳腺癌中透瘤的淋巴细胞

Roberto A Leon-Ferre¹, Sarah Flora Jonas², Roberto Salgado^3,4

¹Department of Oncology, Mayo Clinic, Rochester, Minnesota.

|April 2, 2024

概括

在早期三阴性乳腺癌 (TNBC) 组织中透瘤的淋巴细胞 (TIL) 水平较高,与患者的生存率显著改善有关. 这一发现凸显了TIL丰度作为不接受化疗的TNBC患者的关键预后因素.

科学领域:

癌症学
免疫学

背景情况:

在未接受新辅助或辅助化疗的患者中,瘤透淋巴细胞 (TIL) 在早期三阴性乳腺癌 (TNBC) 的预后意义尚不清楚.
了解TIL的作用对于确定TNBC的预后标志物至关重要,这是一种与较差的结果相关的亚型.

研究的目的:

在仅用局部治疗治疗的早期TNBC患者中,研究TIL在乳腺癌组织中的丰度与生存结果之间的联系.
确定TIL水平是否可以作为该特定患者群体的预后指标.

主要方法:

一项回顾性聚合分析包括1966名在1979年至2017年期间被诊断为TNBC的患者,接受了手术和/或放射治疗,但没有化疗.
在瘤组织中评估了TIL的丰度,并分析了生存结果 (无侵袭性疾病生存率,无复发性生存率,远程无复发性生存率,整体生存率).
通过参与中心分层的多变量考克斯回归模型来评估TIL水平与存活率之间的关联,并根据临床因素进行调整.

主要成果:

与TIL水平较低 (< 30%) 的患者相比,TIL水平较高 (≥ 50%) 的患者远期无复发存活率 (94%) 和整体存活率 (95%) 显著提高.
每增加10%的TIL都与改善的无侵袭性疾病存活率 (HR,0. 92),无复发性存活率 (HR,0. 90),远程无复发性存活率 (HR,0. 87) 和整体存活率 (HR,0. 88) 相关.
该研究分析了北美,欧洲和亚洲1966名TNBC患者的数据,平均随访时间为18年.

结论:

在未接受化疗的早期TNBC患者中,较高的乳腺癌组织TIL丰度与改善的生存结果显著相关.
这些发现确立了TIL丰度作为早期TNBC患者的有价值的预后因素,指导风险分层和治疗决策.

更多相关视频

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...